38 / 62
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 4, July/August 2020
200
AFRICA
so there is a need to further explore the effect of levosimendan
on the haemodynamics. (4) There was no stratified analysis of
clinical endpoints for related factors.
Conclusion
Levosimendan significantly improved NT-proBNP level
and LVEF in our patients with chronic systolic HF, and
improved NYHA cardiac functional class without significant
cardiovascular events. Therefore levosimendan could be an
effective and safe drug for patients with chronic systolic HF.
References
1.
Heart Failure Diagnosis and Treatment Guidelines (China, 2014).
Chinese
J Cardiol
2014;
42
: 98–122.
2.
Liu P, Jiang Y, Li X,
et al
. Efficacy of levosimendan in the treatment of
elderly patients with decompensated heart failure.
Chinese J Gerontol
2016;
36
: 581–582.
3.
Schlecht W, Li KL, Hu D,
et al
. Fluorescence based characterization of
calcium sensitizer action on the troponin complex.
Chem Biol Drug Des
2016;
87
: 171–181.
4.
Çavusoglu Y, Korkmaz S, Demirtas S,
et al
. Ischemia-modified albumin
levels in patients with acute decompensated heart failure treated with
dobutamine or levosimendan: IMA-HF study.
Anatol J Cardiol
2015;
15
:
611–617.
5.
Metra M, Bettari L, Carubelli V,
et al
. Old and new intravenous inotropic
agents in the treatment of advanced heart failure
. Prog Cardiovasc Dis
2011;
54
: 97–106.
6.
Pathak A, Lebrin M, Vaccaro A,
et al
. Pharmacology of levosimendan:
inotropic, vasodilatory and cardioprotective effects.
J Clin Pharm Therapeut
2013;
38
: 341–349.
7.
Dimitrios F, Julian A, Tuvia BG,
et al
. Levosimendan beyond inotropy and
acute heart failure: Evidence of pleiotropic effects on the heart and other
organs: An expert panel position paper
. Int J Cardiol
2016;
222
: 303–312.
8.
He F, Yang G. The impact of levosimendan on mortality in patients with
severe heart failure by meta-analysis.
Chinese Circ J
2015;
30
: 422–427.
9.
Silvetti S, Greco T, Prima AL,
et al
. Intermittent levosimendan improves
mid-term survival in chronic heart failure patients: meta-analysis of
randomised trials.
Clin Res Cardiol
2014;
103
: 505–513.
10. Cao J. Comparison of effect between milrinone and levosimendan applied
in the treatment of acute exacerbation of chronic heart failure.
China Pract
Med
2016;
11
: 12–13.
11. Xu S, Jiang X. A comparative study of levosimendan and milrinone in the
treatment of acute episodes of chronic heart failure.
J Math Med
2015;
28
: 880–881.
12. 12. Gürbüzel M, Sayar I, Cankaya M,
et al
. The preventive role of levosi-
mendan against bleomycin-induced pulmonary fibrosis in rats.
Pharmacol
Rep
2016;
68
: 378–382.
13. 13. Zhang D, Yao Y, Qian J,
et al
. Levosimendan improves clinical
outcomes of refractory heart failure in elderly Chinese patients.
Med Sci
Monit
2015;
21
: 2439–2445.
14. 14. Xing Q, Mang X, Wang L. Effect of recombinant human brain natriu-
retic peptide combined with sodium nitroprusside therapy on hemody-
namics and cardiac in patients with acute decompensated heart failure.
J
Hainan Med Univers
2016;
22
: 1633–1636.
15. 15. Dec GW. Acute decompensated heart failure: the shrinking role of
inotropic therapy.
J Am Coll Cardiol
2005;
46
: 65–67.
16. 16. Gencer E, Do
ğ
an V, Öztürk MT,
et al
. Comparison of the effects of
levosimendan dobutamine and vasodilator therapy on ongoing myocardial
injury in acute decompensated heart failure.
J Cardiovasc Pharmacol Ther
2017;
22
: 153–158.
17. 17. Kivikko M, Antila S, Eha J,
et al
. Pharmacokinetics of levosimendan
and its metabolites during and after a 24-hour continuous infusion in
patients with severe heart failure.
Int J Clin Pharmacol Ther
2002;
40
:
465–471.
18. 18. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896,
an active metabolite of levosimendan, on canine ventricular myocardium.
Eur J Pharmacol
2000;
400
: 103–112.
19. 19. Rocha BML, Menezes Falcão L. Acute decompensated heart failure
(ADHF): A comprehensive contemporary review on preventing early
readmissions and postdischarge death.
Int J Cardiol
2016;
223
: 1035
–
1044.
20. 20. Hao G, Gao G, Fan W,
et al
. Efficacy and safety of levosimendan in the
treatment of elderly patients with chronic heart failure.
Chinese Gen Pract
2015;
18
: 3153–3157.
21. 21. Mao R, Chen J, Zhang Y. Effects of plasma N-terminal pro-brain
natriuretic peptide for the nursing in chronic heart failure patients.
Chinese
J Med Guide
2015;
12
: 1282–1284.
22. 22. Zhang Y, Zhang J, Qing E,
et al
. Comparison on efficacy and safety
between domestic levosimendan versus dobutamine for patients with acute
decompensated heart failure.
Chinese J Cardiol
2012;
40
: 153–156.
23. 23. Wang Z, Wang X, Zhang X,
et al
. Effects of levosimendan on cardiac
function and N-terminal pro-brain natriuretic peptide in patients with
refractory heart failure.
Chinese J Evidence-Based Cardiovasc Med
2017;
9
: 944–946.
24. 24. Follath F, Cleland JG, Just H,
et al
. Efficacy and safety of intravenous
levosimendan compared with dobutamine in severe low-output heart
failure (the LIDO study): a randomised double-blind trial.
Lancet
2002;
360
: 196–202.
25. 25. Moiseyev VS, Poder P, Andrejevs N,
et al
. Safety and efficacy of a novel
calcium sensitizer, levosimendan, in patients with left ventricular failure
due to an acute myocardial infarction. A randomized, placebo-controlled,
double-blind study (RUSSLAN).
Eur Heart J
2002;
23
: 1422–1432.
26. 26. Cleland JG, Ghosh J, Freemanth N,
et al
. Clinical trials update and
cumulative meta-analyses from the American College of Cardiology:
WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US,
RIO-Lipids and cardiac resynchronisation therapy in heart failure
. Eur J
Heart Fail
2004;
6
: 501–508.
27. 27. Wang L, Cui L, Wei J,
et al.
Efficacy and safety of intravenous levo-
simendan compared with dobutamine in decompeusated heart failure.
Chinese J Cardiol
2010;
38
: 527–530.
28. 28. Kivikko M, Antila S, Eha J,
et al
. Pharmacodynamics and safety of
a new calcium sensitizer, levosimendan,and its metabolites during an
extended infusion in patients with severe heart failure.
J Clin Pharmacol
2002;
42
: 43–51.
29. 29. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new
cardiac enhancers.
Heart Fail Rev
2007;
12
: 149–156.
30. 30. Silvetti S, Silvani P, Azzolini ML,
et al
. A systematic review on levo-
simendan in paediatric patients.
Curr Vasc Pharmacol
2015;
13
: 128–133.